Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julie M Vose

Showing results (171-180 of 299) with videos related to

Pageof 30
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|July 26, 2005
Senior adult oncology clinical practice guidelines in oncologyLodovico Balducci, Harvey Jay Cohen, Paul F Engstrom, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 5, 2005
Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphomaMyron S Czuczman, Aron Thall, Thomas E Witzig, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2008
Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphomaKai Fu, Dennis D Weisenburger, William W L Choi, et al.
Cancer|April 19, 2012
Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapyJorge J Castillo, Michael Furman, Brady E Beltrán, et al.
British Journal of Haematology|April 23, 2013
B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and burkitt lymphoma: study of 39 casesAnamarija M Perry, David Crockett, Bhavana J Dave, et al.
British Journal of Haematology|May 22, 2023
Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell lymphomaRobert Stuver, Steven M Horwitz, Ranjana H Advani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 8, 2010
Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximabPaul N Meyer, Kai Fu, Timothy C Greiner, et al.
Blood|March 5, 2004
Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphomaAndres Forero, Paul L Weiden, Julie M Vose, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 16, 2010
NCCN Oncology Risk Evaluation and Mitigation Strategies White Paper: Recommendations for StakeholdersPhilip E Johnson, George Dahlman, Kirby Eng, et al.
British Journal of Haematology|January 29, 2014
A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab eraPeter J Hosein, Jocelyn C Maragulia, Matthew P Salzberg, et al.
Pageof 30

Showing results (171-180 of 299) with videos related to

Sort By:
Pageof 30
Journal of the National Comprehensive Cancer Network : JNCCN|July 26, 2005
Senior adult oncology clinical practice guidelines in oncologyLodovico Balducci, Harvey Jay Cohen, Paul F Engstrom, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 5, 2005
Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphomaMyron S Czuczman, Aron Thall, Thomas E Witzig, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2008
Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphomaKai Fu, Dennis D Weisenburger, William W L Choi, et al.
Cancer|April 19, 2012
Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapyJorge J Castillo, Michael Furman, Brady E Beltrán, et al.
British Journal of Haematology|April 23, 2013
B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and burkitt lymphoma: study of 39 casesAnamarija M Perry, David Crockett, Bhavana J Dave, et al.
British Journal of Haematology|May 22, 2023
Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell lymphomaRobert Stuver, Steven M Horwitz, Ranjana H Advani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 8, 2010
Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximabPaul N Meyer, Kai Fu, Timothy C Greiner, et al.
Blood|March 5, 2004
Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphomaAndres Forero, Paul L Weiden, Julie M Vose, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 16, 2010
NCCN Oncology Risk Evaluation and Mitigation Strategies White Paper: Recommendations for StakeholdersPhilip E Johnson, George Dahlman, Kirby Eng, et al.
British Journal of Haematology|January 29, 2014
A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab eraPeter J Hosein, Jocelyn C Maragulia, Matthew P Salzberg, et al.
Pageof 30